Navlimetostat clinical trials
Navlimetostat is named as an intervention in 10 current clinical trials in our USA, China, Spain, Japan, Germany, France, Italy, UK, Netherlands, Belgium, Sweden, Poland, Canada, South Korea, Australia, Ireland, India, Denmark, Austria, Czechia, Turkey, Brazil, Mexico, Taiwan, Israel, Norway, Switzerland and Singapore registers. 9 are recruiting patients now. The most common phase is Phase 1. The lead sponsor is Bristol-Myers Squibb. The most-studied condition is Pancreatic Ductal Adenocarcinoma.
Patient leaflets for Navlimetostat
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Navlimetostat
10 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Navlimetostat
13 conditionsAll 13 conditions
| Condition (as registered) | Trials |
|---|---|
| Pancreatic Ductal Adenocarcinoma | 1 |
| Solid Tumors | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Healthy Female Participants | 1 |
| Healthy Participants | 1 |
| Healthy Female Adults | 1 |
| Metastatic Non-small Cell Lung Cancer With MTAP Deletion | 1 |
| Advanced Solid Tumors | 1 |
| Advanced Solid Tumors With Homozygous MTAP Deletion | 1 |
| Mesothelioma | 1 |
| Non Small Cell Lung Cancer | 1 |
| Malignant Peripheral Nerve Sheath Tumors | 1 |
| Solid Tumor | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Bristol-Myers Squibb | 10 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Navlimetostat trials
How many clinical trials are testing Navlimetostat?
10 current trials in our USA, China, Spain, Japan, Germany, France, Italy, UK, Netherlands, Belgium, Sweden, Poland, Canada, South Korea, Australia, Ireland, India, Denmark, Austria, Czechia, Turkey, Brazil, Mexico, Taiwan, Israel, Norway, Switzerland and Singapore registers name Navlimetostat (also registered as BMS-986504) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Navlimetostat trials recruiting patients?
Yes. 9 of the 10 trials are recruiting: 6 with sites in USA, 4 with sites in China, 4 with sites in Spain, 4 with sites in Japan, 3 with sites in Germany, 3 with sites in France, 3 with sites in Italy, 2 with sites in UK, 2 with sites in Netherlands, 2 with sites in Belgium, 2 with sites in Sweden, 2 with sites in Poland, 2 with sites in Canada, 2 with sites in South Korea, 2 with sites in Australia, 1 with sites in Ireland, 1 with sites in India, 1 with sites in Denmark, 1 with sites in Austria, 1 with sites in Czechia, 1 with sites in Turkey, 1 with sites in Brazil, 1 with sites in Mexico, 1 with sites in Taiwan, 1 with sites in Israel and 2 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Navlimetostat clinical trials?
The lead sponsor is Bristol-Myers Squibb. The number in brackets is how many trials each organisation leads.
Are there Navlimetostat clinical trials in Ireland?
Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Navlimetostat works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Navlimetostat works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Navlimetostat (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.